Today on TheBrief
Fast, reliable briefs on the latest medical research. Each one gives you the finding, the population it applies to, what it changes in practice, and a link straight to the original source.
Cardiology
An FDA early alert flags an Edwards transcatheter mitral-valve delivery system, but the available record does not name a model, event count or corrective action.
Dr. Abu Bakar · November 2, 2026 · 6 min
Endocrinology & Metabolism
The FDA boxed warning highlights serious hypophosphatemia with ferric carboxymaltose, particularly after repeated exposure. Treatment selection should now include phosphate risk, counseling and monitoring needs.
Dr. Abu Bakar · 7 min read
Cardiology
The multicenter BASE trial will test cardiovascular and metabolic effects of beta-blocker therapy in people with aortic stenosis. Its protocol does not yet provide treatment-effect estimates.
Rayan Salih · 6 min read
Endocrinology & Metabolism
FDA approval of insulin efsitora alfa-gobe creates a weekly basal insulin option for adults with type 2 diabetes, making treatment burden, hypoglycemia risk and follow-up capacity central to selection.
Rayan Salih · 7 min read
Health Policy
The FDA authorized dostarlimab for eligible adults with stage II or III locally advanced rectal cancer, based on a 154-patient efficacy assessment. Confirmation of long-term clinical benefit is still required.
Rayan Salih · 7 min read
Heart and vascular medicine
Trial results, device approvals and practice guidance across cardiology, interventional care and vascular medicine.
Cancer care and research
Practice-changing oncology and hematology research, from early detection through survivorship.
Brain, nerve and cognitive care
Neurology and neuroscience briefs covering diagnosis, disease-modifying therapy and long-term management.
Diabetes, obesity and hormone health
Metabolic medicine: glycemic management, GLP-1 therapeutics, thyroid disease and endocrine practice.
OBGYN and women's medicine
Obstetric, gynecologic and women's health evidence across the reproductive lifespan.
Psychiatry and behavioral medicine
Psychiatry, behavioral health and sleep medicine research with an eye on what changes in clinic.
Infection, immunity and prevention
Infectious disease, immunology and infection prevention, from outbreak response to vaccine evidence.
Regulation, coverage and access
Policy, payment and public health decisions that shape how clinicians practice and patients get care.
Technology at the bedside
Medical devices, diagnostics, digital health and AI tools moving from pipeline into practice.
Reporting from the meetings
Late-breaking data and session highlights from the major medical congresses.
Across the specialties
Concise evidence briefs from across internal medicine, surgery, pediatrics and primary care.
Infectious Disease
The Class I recall applies to specified Medline convenience kits containing recalled BD ChloraPrep applicators. Hospitals and other users should match both kit identifiers and lots against the FDA notice.
Dr. Abu Bakar · 6 min read
Oncology
The FDA approved talazoparib plus enzalutamide for adults with HRR-mutated metastatic prostate cancer that remains naïve or sensitive to androgen-pathway modulation. An FDA-authorized test must confirm eligibility.
Dr. Abu Bakar · 7 min read
Conference Coverage
Alpha and beta emitters bring distinct dosimetry, manufacturing and safety challenges. A conference review highlights why their development cannot be judged as a cross-cancer efficacy contest.
Dr. Abu Bakar · 7 min read
Neurology
The FDA-labeled population for FAYUVI is pediatric patients with MPS IIIA and preserved neurodevelopmental function, making timely developmental assessment central to treatment selection.
Rayan Salih · 6 min read
Oncology
Accelerated approval adds dostarlimab as an initial option for selected patients with untreated stage II or III MSI-H or dMMR rectal cancer, making organ preservation an early multidisciplinary decision.
Rayan Salih · 6 min read
Clinical Briefs
Traditional approval retains a narrow, tissue-agnostic indication for adults and children with previously treated, unresectable or metastatic TMB-high solid tumors and no satisfactory alternatives.
Rayan Salih · 6 min read
Oncology
The FDA has moved pirtobrutinib into previously untreated CLL and SLL, expanding first-line choice when therapy is indicated rather than reserving the drug for later lines.
Rayan Salih · 6 min read
Oncology
Accelerated approval makes dostarlimab an initial option for previously untreated stage II or III MSI-H/dMMR rectal cancer, with the possibility of avoiding chemotherapy, radiation and surgery.
Rayan Salih · 6 min read
One story a day
One health journey each morning — no advice, no alarm, just company for the road.
Oncology
FDA traditional approval defines TMB-high solid tumors as at least 13 mutations per megabase. Eligibility depends on confirming that the reported result meets the new cutoff.
Rayan Salih · 7 min read
Oncology
The FDA approved lirafugratinib for previously treated cholangiocarcinoma with an FGFR2 fusion or other rearrangement, adding a biomarker-defined option after earlier therapy.
Dr. Abu Bakar · 6 min read
Women's Health
The FDA approved imlunestrant plus abemaciclib for adults with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after endocrine progression. ESR1 testing now determines eligibility.
Dr. Abu Bakar · 6 min read
Innovation & Devices
Updated Amplatzer Amulet instructions sort pulmonary artery injury risk into three distance bands for patients undergoing left atrial appendage closure.
Dr. Abu Bakar · 6 min read
Oncology
In a phase 3 head-to-head trial, [177Lu]Lu-edotreotide extended progression-free survival compared with everolimus in progressive, somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
Rayan Salih · 6 min read
Women's Health
The FDA approval applies to adults with ER-positive, HER2-negative advanced or metastatic breast cancer harboring an ESR1 mutation after endocrine-therapy progression. Guardant360 CDx is the companion diagnostic.
Rayan Salih · 7 min read
Amanda Gray
Contributing writer · PA
A board-certified Physician Assistant who has been practicing medicine since 2008. My clinical experience includes occupational medicine, urgent care, family medicine, and cardiology, with the majority of my career…
Egbavwe Pela
Contributing writer
Dr. Abu Bakar
Contributing writer · PharmD, PhD (Pharmacology)
A Pharm-D and PhD in Pharmacology from Punjab University College of Pharmacy, and I have worked as a registered hospital pharmacist at Jinnah Hospital Lahore. Over the past six years in clinical practice, I have seen…
Rayan Salih
Contributing writer · PharmD, RPh
Rayan is a pharmacist, life science communicator, and health policy researcher with a deep interest in ensuring patient access to innovative and life-changing therapies. She obtained her PharmD at Rosalind Franklin…